Top

Published in:

01-12-2008 | PRECLINICAL STUDIES

Aberrant crypt foci and AgNORs as putative biomarkers to evaluate the chemopreventive efficacy of pronyl-lysine in rat colon carcinogenesis

Authors: Jayabal Panneer Selvam, Selvaraj Aranganathan, Namasivayam Nalini

Published in: Investigational New Drugs | Issue 6/2008

Summary

Chemoprevention opens new perspectives in the prevention of cancer and other degenerative diseases. Use of target-organ biological models at the histological and genetic levels can markedly facilitate the identification of potential chemopreventive agents. Our aim was to study the chemopreventive efficacy of pronyl-lysine, a key antioxidant present in bread crust by evaluating, the total number of aberrant crypt foci (ACF), their distributions, dysplastic ACF, colonic tumor incidence and the expression of cell proliferation biomarker such as the argyrophilic nucleolar organizing region-associated proteins (AgNORs) in 1,2-dimethylhydrazine (DMH) induced colon cancer in rats. Male Wistar rats were randomized into seven groups, group 1 were control rats, group 2 received pronyl-lysine (2 mg/kg body weight p.o. everyday), rats in groups 3–7 were administered DMH (20 mg/kg body weight) in the groin for 15 weeks. In addition, group 4 (pre-initiation), 5 (initiation), 6 (post-initiation), and 7 (entire period) received pronyl-lysine (2 mg/kg body weight p.o) everyday. At the end of 34 weeks, pronyl-lysine supplementation showed markedly reduced tumor incidence, ACF development and also lowered number of AgNORs. Overall, these findings confirm that pronyl-lysine has a positive beneficial effect against chemically induced colonic preneoplastic progression in rats.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMed

Sinha R, Anderson DE, McDonald SS, Greenwald P (2003) Cancer risk and diet in India. J Postgrad Med 49:222–228PubMed

Sengottuvelan M, Viswanathan P, Nalini N (2006) Chemopreventive effect of trans-resveratrol-a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis 27:1038–1046PubMedCrossRef

Deeptha K, Kamaleeswari M, Sengottuvelan M, Nalini N (2006) Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine induced colonic aberrant crypt foci and bacterial enzyme activity in rats. Invest New Drugs 24:479–488PubMedCrossRef

Lindenmeier M, Faist V, Hofmann T (2002) Structural and functional characterization of pronyl-lysine, a novel protein modification in bread crust melanoidins showing in vitro antioxidative and phase I/II enzyme modulating activity. J Agric Food Chem 50:6997–7006PubMedCrossRef

Marko D, Kemeny M, Bernady E, Habermeyer M, Weyand U, Meiers S, Frank O, Hofmann T (2002) Studies on the inhibition of tumor cell growth and microtubule assembly by 3-hydroxy-4-[(E)-(2-furyl) methylidene]methyl-3-cyclopentene-1,2-dione, an intensively coloured Maillard reaction product. Food Chem Toxicol 40:9–18PubMedCrossRef

Somoza V, Wenzel E, Lindenmeier M, Grothe D, Erbersdobler HF, Hofmann T (2005) Influence of feeding malt, bread crust, and a pronylated protein on the activity of chemopreventive enzymes and antioxidative defense parameters in vivo. J Agric Food Chem 53:8176–8182PubMedCrossRef

Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB (1997) Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrixcoated permeable supports in the presence of 1-alpha, 25-dihydroxyvitamin D3. Mol Pharmacol 51:741–754PubMed

Wilkinson J, Clapper ML (1997) Detoxication enzymes and chemoprevention. Proc Soc Exp Biol Med 216:192–200PubMed

10.

Somoza V, Lindenmeier M, Hofmann T, Frank O, Erbersdobler Hf, Baynes Jw, Thorpe Sr, Heidland A, Zill H, Bek S, Huber J, Weigle T, Scheidler S, Busch Ae, Sebekova K (2005) Dietary bread crust advanced glycation end products bind to the receptor for AGEs in HEK-293 kidney cells but are rapidly excreted after oral administration to healthy and subtotally nephrectomized rats. Ann NY Acad Sci 1043:492–500PubMedCrossRef

11.

McLellan EA, Medline A, Bird RP (1991) Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions. Cancer Res 51:5270–5274PubMed

12.

Yamada Y, Mori H (2003) Pre-cancerous lesions for colorectal cancers in rodents: a new concept. Carcinogenesis 24:1015–1019PubMedCrossRef

13.

Bird RP (1995) Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 93:55–71PubMedCrossRef

14.

Hirose Y, Kuno T, Yamada Y, Sakata K, Katayama M, Yoshida K, Qiao Z, Hata K, Yoshimi N, Mori H (2003) Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis 24:107–111PubMedCrossRef

15.

Wargovich MJ, Chen CD, Jimenez A, Steele VE, Velasco M, Stephens LC, Price R, Gray K, Kelloff GJ (1996) Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol Biomarkers Prev 5:355–360PubMed

16.

Thorup I (1997) Histomorphological and immunochemical characterization of colonic aberrant crypt foci in rats: relation to growth factor expression. Carcinogenesis 18:465–472PubMedCrossRef

17.

Yamada Y, Mori H (2003) Pre-cancerous lesions for colorectal cancers in rodents: a new concept. Carcinogenesis 24:1015–1019PubMedCrossRef

18.

Ruschoff J, Plate K, Bittinger A, Thomas C (1989) Nucleolar organizer regions (NORs). Basic concepts and practical application in tumor pathology. Pathol Res Pract 185:878–885PubMed

19.

Contractor H, Ruschoff J, Hanisch T, Ulshofer B, Neumann K, Schultze-Seemann W, Thomas C (1991) Silver-stained structures in prostatic carcinoma: evaluation of diagnostic and prognostic relevance by automated image analysis. Urol Int 46:9–14PubMedCrossRef

20.

Risio M, Rossini FP (1993) Cell proliferation in colorectal adenomas containing invasive carcinoma. Anticancer Res 13:43–47PubMed

21.

Ruschoff J, Zimmermann R, Ulshofer B, Thomas C (1992) Silver-stained nucleolar organizer proteins in urothelial bladder lesions. A morphometric study. Pathol Res Pract 188:593–598PubMed

22.

Lindenmeier M, Hofmann T (2004) Influence of baking conditions and precursor supplementation on the amounts of the antioxidant pronyl-L-lysine in bakery products. J Agric Food Chem 52:350–354PubMedCrossRef

23.

Ochiai M, Watanabe M, Nakanishi M, Taguchi A, Sugimura T, Nakagama H (2005) Differential staining of dysplastic aberrant crypt foci in the colon facilitates prediction of carcinogenic potentials of chemicals in rats. Cancer Lett 220:67–74PubMedCrossRef

24.

Nyska A, Zusman I, Klein T, Sheila N, Weis O, Madar Z, Klein B (1995) Assessment of the nucleolar organizer regions by automated image analysis in benign and malignant colonic tumours and adjacent tissues in rats. J Comp Pathol 113:45–50PubMedCrossRef

25.

Tanaka T, Makita H, Kawamori T, Kawabata K, Mori H, Murakami A, Satoh K, Hara A, Ohigashi H, Koshimizu K (1997) A xanthine oxidase inhibitor 1′-acetoxychavicol acetate inhibits azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis 18:1113–1118PubMedCrossRef

26.

Kanna PS, Mahendrakumar CB, Chakraborty T, Hemalatha P, Banerjee P, Chatterjee M (2003) Effect of vanadium on colonic aberrant crypt foci induced in rats by 1,2 dimethyl hydrazine. World J Gastroenterol 9:1020–1027PubMed

27.

Agner AR, Bazo AP, Ribeiro LR, Salvadori DM (2005) DNA damage and aberrant crypt foci as putative biomarkers to evaluate the chemopreventive effect of annatto (Bixa orellana L.) in rat colon carcinogenesis. Mutat Res 582:146–154PubMed

28.

Lipkin M (1988) Biomarkers of increased susceptibility to gastrointestinal cancer: new application to studies of cancer prevention in human subjects. Cancer Res 48:235–245PubMed

29.

Bird RP, Good CK (2000) The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 112–113:395–402PubMedCrossRef

30.

Kawamori T, Tanaka T, Hara A, Yamahara J, Mori H (1995) Modifying effects of naturally occurring products on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats. Cancer Res 55:1277–1282PubMed

31.

Waitzberg DL, Goncalves EL, Faintuch J, Bevilacqua LR, Rocha CL, Cologni AM (1989) Effect of diets with different protein levels on the growth of Walker 256 carcinosarcoma in rats. Braz J Med Biol Res 22:447–455PubMed

32.

Poulsen M, Molck AM, Thorup I, Breinholt V, Meyer O (2001) The influence of simple sugars and starch given during pre- or post-initiation on aberrant crypt foci in rat colon. Cancer Lett 167:135–143PubMedCrossRef

33.

Yamaguchi A, Tsukioka Y, Kurosaka Y, Nishimura G, Kanno M, Yonemura Y, Mivazaki I (1993) Prognostic value of nucleolar organizer regions in endoscopically biopsied tissues of colorectal cancers. Oncology 50:121–126PubMedCrossRef

34.

Wong WM, Wright NA (1999) Cell proliferation in gastrointestinal mucosa. J Clin Pathol 52:321–333PubMed

Title: Aberrant crypt foci and AgNORs as putative biomarkers to evaluate the chemopreventive efficacy of pronyl-lysine in rat colon carcinogenesis
Authors: Jayabal Panneer Selvam
Selvaraj Aranganathan
Namasivayam Nalini
Publication date: 01-12-2008
Publisher: Springer US
Published in: Investigational New Drugs / Issue 6/2008
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-008-9122-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 6/2008

Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors

Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer

Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease

Optimal modeling for phase I design of a two drug combination—results of a phase I study of cisplatin with 9-nitrocamptothecin

CPT21, a novel compound with anti-proliferative effect against gastric cancer cell SGC7901

Evaluation of the therapeutic efficacy of tripeptide tyroserleutide (YSL) for human hepatocarcinoma by in vivo hollow fiber assay

Keynote webinar | Spotlight on antibody–drug conjugates in cancer